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Edited by Gianni CesareniAbstract Src-homology (SH3) domain belongs to a class of
ubiquitous modular protein domains found in nature. SH3 do-
mains have a conserved surface that recognises proline-rich pep-
tides in ligand proteins, but additional contacts also contribute to
binding. Using the SH3 domain of hematopoietic cell kinase as a
test case, we show that SH3 binding properties can be profoundly
altered by modiﬁcations within a hexapeptide sequence in the
RT-loop region that is not involved in recognition of currently
known consensus SH3 target peptides. These results highlight
the role of non-conserved regions in SH3 target selection, and
introduce a strategy that may be generally feasible for generat-
ing artiﬁcial SH3 domains with desired ligand binding proper-
ties.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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transduction1. Introduction
Src-homology (SH3) domains are small protein modules
that mediate inter- and intramolecular protein interactions,
and are often found in proteins involved in cellular signalling
pathways, cytoskeletal organisation, and membrane traﬃcking
(for reviews, see [1,2]). SH3 domains recognise short proline
rich sequences typically containing a core PxxP binding motif
(where P is proline and x is any amino acid) ﬂanked on either
side by a basic residue that determines the orientation of bind-
ing. However, several atypical SH3-binding sites lacking a con-
ventional PxxP consensus sequence have also have been
described (e.g. [3–5]).
PxxP and other core binding motifs serve as critical docking
sites for SH3 domains, but additional molecular contacts out-
side this conserved interaction interface often help to improve
the speciﬁcity and aﬃnity of SH3 binding. These additional
contacts may involve secondary structures that are adjacentAbbreviations: SH3, Src-homology; Hck, hematopoietic cell kinase;
HIV-1; human immunodeﬁciency virus type-1; SIV, simian immuno-
deﬁciency virus; Nef, negative factor; RRT, randomised RT-loop;
PAK1, p21-activated kinase-1
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doi:10.1016/j.febslet.2007.03.044to the PxxP motif in the polypeptide chain of the ligand pro-
tein [6,7], but may also be located distantly. A good example
of the latter arrangement is provided by the human immuno-
deﬁciency virus type-1 (HIV-1) negative factor (Nef) protein.
The SH3 domain of hematopoietic cell kinase (Hck) binds
strongly to Nef (KD 0.25 lM), whereas the aﬃnity of the re-
lated Src-family kinase SH3 domain of Fyn is much lower
[8]. X-ray crystallographic and mutagenesis studies have re-
vealed that residues in the tip of the RT-loop, which is the
most variable region among diﬀerent SH3 domains, account
for the strong and speciﬁc binding Nef-binding by Hck-SH3
[9,10]. These RT-loop residues of Hck-SH3 are not involved
in recognition of the PxxP motif of Nef, and instead contact
a hydrophobic pocket on the opposite side, which is formed
by multiple residues positioned apart from each other in the
Nef polypeptide.
We have shown previously that binding of Hck-SH3 to Nef
can be further increased via phage display-mediated optimisa-
tion of six residues in this non-conserved RT-loop region [11].
These engineered molecules (dubbed RRT-SH3 for rando-
mised RT-loop) could act as potent inhibitors of Nef function
when introduced in cultured cells [12]. In this study we have
examined the general feasibility of this strategy, and show that
diverse SH3 ligands, including proteins with little or no aﬃnity
for unmodiﬁed Hck-SH3, can be eﬀectively targeted by such
RRT-SH3 domains. These results highlight the contribution
of SH3 residues outside of the conserved peptide-binding
groove in ligand recognition, and show that manipulation of
the RT-loop is a powerful strategy to generate artiﬁcial SH3
domains with desired ligand binding properties.2. Materials and methods
2.1. Expression vectors and recombinant protein puriﬁcation
To produce the ligands for SH3-phage binding the intracellular do-
mains of CD3e (residues 131–185) and ADAM15 (residues 711–862,
[13]), the amino terminal fragment of p21-activated kinase-1 (PAK1)
(residues 1–272), the carboxyterminal fragment of Sos1 (residues
1135–1333), and the complete coding region of the PI3K p85a regula-
tory subunit were cloned into the pGEX-4T-1 vector (GE Healthcare
Bio-Sciences, Uppsala, Sweden). Expression and puriﬁcation of the
resulting GST fusion proteins in Escherichia coli were carried out
according to manufacturer’s instructions. After glutathione elution
the proteins were concentrated in PBS with Amicon Ultra 4 columns
(Millipore, Billerica, MA, USA).
2.2. Phagemids and phage display
The multivalent library of artiﬁcial Hck-derived SH3 domains was
created into pG8H6 [14] as described before [15]. Brieﬂy, by using a
degenerate PCR primer six amino acid residues of human Hck-SH3blished by Elsevier B.V. All rights reserved.
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domised and the resulting RRT-SH3 fragments were cloned as fusion
proteins to the phage coat protein VIII carrying an N-terminal Myc
epitope tag. In addition, a TAG stop codon was placed in front of
the RRT-SH3 insert to reduce expression of the fusion protein in a
supE host (TG1 strain of E. coli) in which amber termination is incom-
pletely suppressed. RRT-SH3 clones previously selected with HIV-1
Nef using a monovalent phage system [12] as well as unmodiﬁed
Hck-SH3 were individually inserted into the multivalent pG8H6 vector
by PCR-assisted cloning. Recombinant phages were produced via
infection with the M13KO7 helper phage and screened with recombi-
nant fusion proteins immobilised on six-well plates as described previ-
ously [11].
2.3. Phage-assisted SH3-binding assay
MaxiSorp wells (Nalge Nunc, Rochester, NY, USA) were coated
with 200 ng of puriﬁed GST-ligand fusion proteins or plain GST in
50 ll of TBS overnight at 4 C. Alternatively the wells were coated
with 100 ng of anti-Myc antibody 9E10 (Sigma–Aldrich, St. Louis,
MO, USA). Wells were washed three times with washing buﬀer
(WB; TBS/0.05% Tween 20) followed by an hour incubation with
2% milk in TBS at room temperature, and washed again three times
with WB. Supernatants of the recombinant multivalent phage clones
expressing the RRT-SH3 domains fused to a Myc epitope tag (titres
>1011 pfu/ml) were added to wells and incubated for 2 h at room tem-
perature. The wells were washed three times with WB, and peroxidase
conjugated anti-M13 antibody (GE Healthcare Bio-Sciences) was
added to wells and incubated for an hour. Wells were washed three
times with WB and 50 ll of the ready-to-use substrate 2,2 0-Azino-βA βB
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Fig. 1. Structure of the SH3 domain of Hck. The six residues (E90AIHHE95)
dashed circle indicates the groove accommodating the core binding peptide of
are key structural components of one of the two proline-binding pockets in th
structure of Hck-SH3 is shown below the 3-D structure. Amino acid number
was obtained from Protein Data Bank and styled with DS Visualizer.bis(3-ethylbenzthiazoline-6-sulfonic acid (ABTS; Sigma–Aldrich) was
added per well. The enzymatic reactions were stopped after 30 min
by adding 50 ll of 1% SDS, followed by optical density measurement
at 405 nm. After background subtraction the readings were normalised
based on the corresponding readings from the anti-Myc-coated wells.3. Results
In our earlier studies aimed at improving binding of Hck-
SH3 to HIV-1 and simian immunodeﬁciency virus (SIV) Nef
proteins [11,15] we have generated large mono- and multiva-
lent phage libraries displaying Hck-derived RRT-SH3 do-
mains carrying random hexapeptide sequences in the RT-
loop region (Fig. 1). The success in these studies prompted
us to investigate the potential of the RT-loop as a general spec-
iﬁcity/aﬃnity-determining region in SH3 ligand recognition.
To test this idea we selected as potential RRT-SH3 targets a
panel of known SH3 ligand proteins that serve important roles
in cellular signal transduction, namely CD3e, ADAM15,
PAK1, Sos1, and p85a (the regulatory unit of PI3K), and ex-
pressed these as GST fusion proteins in E. coli. Previous stud-
ies have shown that ADAM15 and PAK1, but not p85a,
CD3e, or Sos1 can bind to Hck-SH3 [13,16]. With the excep-
tion of p85a, expression of full-length versions of these pro-310βC βD βE
distal loop
129124119114 136132
βA
βC
βE310
N131
Y132
in the RT-loop subjected to sequence manipulation are indicated. The
the ligand, and two highly conserved amino acids (N131 and Y132) that
is groove are also shown. A schematic representation of the secondary
ing is according to full-length human Hck. The structure (5HCK; [21])
Table 1
RT-loop sequences found in RRT-SH3 domains selected for optimal
binding to diﬀerent ligands
Ligand SH3 domain RT-loop
– Hck SH3 EAIHHE
Nef A1 VSWSPD
A2 FSWSDT
B4 FSPFDW
B6 YSPFSW
C1 TSPFPW
PAK1 P1 GGLYAD
P2 MPLYVG
P3 NPLYVG
P4 LPLYMG
P5 DAVYMD
ADAM15 15.1 TGEDRN
15.2 IAYGDG
15.3 MAQCIG
15.4 RAEQSG
15.5 DGVLVG
CD3e e1 WGRNAM
e2 LATNRY
e3 TRANVF
e4 WGRNRL
e5 VARATP
Sos1 S1 GAMEVG
S2 VGSEYD
S3 REVYEG
S4 QEEMPG
S5 RALELG
PI3K p85a 85.1 VGTEYG
85.2 WAEEVG
85.3 EALEYG
85.4 MALWEG
85.5 GGLYWD
Shown is the hexapeptide region subjected to modiﬁcations in Hck-
SH3 (see Fig. 1), and the corresponding residues in RRT-SH3 clones
targeted for binding to the indicated ligands.
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remaining ligand proteins the relevant domains harbouring
their SH3-binding motifs were expressed. In case of the trans-
membrane proteins CD3e and ADAM15 the complete intra-
cellular domain was chosen (residues 131–185 and 711–862,
respectively), whereas the regulatory domain of PAK1 (resi-
dues 1–272) and the carboxyterminal domain of Sos1 (residues
1135–1333) were used.
Six-well plastic plates were coated with these fusion proteins
or plain GST as a control, and incubated with a multivalent
phage library expressing approximately 420 million individual
RRT-SH3 clones fused to the M13 coat protein pVIII. After
washing of the wells, E. coli cells were infected by the bound
phages, and used to generate a secondary ampliﬁed sublibrary
via M13KO7 helper virus infection. After four such rounds of
selection and ampliﬁcation, the titre of infectious phages asso-
ciated with the GST-ligand fusion protein used for their selec-
tion was signiﬁcantly higher than with plain GST tested as a
control (data not shown). Several (typically 10) bacterial colo-
nies from each plate were chosen for further analysis. Phage-
mid DNA was isolated from these colonies to determine the
RT-loop sequence in these RRT-SH3 clones. Typically, the
RT-loops of two or three of the clones selected using the same
ligand were identical, and the remaining clones showed varying
degree of similarity to each other (Table 1 and data not
shown).
Individual infectious phage supernatants were generated
from each unique clone, and their ability to bind to their cog-
nate ligands was conﬁrmed based on counting of target pro-
tein-associated infectious phage titres as above. In all cases,
these clonal phage preparations bound to the protein used
for their selection much better than to plain GST (not shown).
Table 1 shows the RT-loop hexapeptide found in place of the
natural Hck-SH3 sequence (EAIHHE) in ﬁve RRT-SH3 do-
mains, which based on this initial functional characterisation
appeared to bind particularly well to their target protein.
For comparison Table 1 also shows RT-loop sequences of ﬁve
RRT-SH3 clones previously derived via extensive selection of
optimal binders to HIV-1 Nef from a monovalent phage li-
brary [11]. To include these Nef-targeted SH3 domains for
comparison into studies aimed at functional characterisation
of the novel RRT-SH3 clones, the former were also cloned into
the same multivalent M13 phage system used for aﬃnity selec-
tion in this study.
Similar to our earlier work on HIV-1 and SIV Nef proteins
[11,15], RT-loop sequences of RRT-SH3 domains selected
with a given ligand protein were heterogeneous, but yet
showed signiﬁcant homology to each other (see Table 1). By
contrast, the sets of RRT-SH3 domains selected with diﬀerent
ligands showed little similarity to each other, or to those se-
lected earlier with HIV-1 Nef. The only exception in this re-
gard was that a glycine residue often appeared in the last
randomised RT-loop position in RRT-SH3 domains targeted
for binding to ADAM15, PAK1, Sosl, and p85a. None of
these hexapeptides matched with an RT-loop sequence found
in a natural SH3 domain.
Three RRT-SH3 domains targeted against each ligand pro-
tein were selected for more detailed functional studies. To
characterise their binding properties we developed a semi-
quantitative interaction assay similar to that described by Win-
ter and colleagues [17]. As illustrated in Fig. 2, this assay was
based on recognition of immobilised SH3 ligand proteins byRRT-SH3 domains expressed on the surface of phage parti-
cles, followed by detection of the bound SH3 domains using
an enzyme-conjugated anti-phage antibody. Following deter-
mination and normalisation of the infectious titre of these
phages, the amount of RRT-SH3 domains available for li-
gand-speciﬁc binding on their surface was determined by mea-
suring in parallel the eﬃciency of capture of the same phages
by an immobilised monoclonal antibody against a Myc peptide
epitope present in each phage between the RRT-SH3 domain
and the pVIII coat protein (see Fig. 2). The ratio of speciﬁc li-
gand binding vs. anti-Myc binding was then used as a measure
of the relative aﬃnity of the displayed RRT-SH3 domains for
their cognate ligands.
As shown in Fig. 3, in the case of each of the ﬁve ligand pro-
teins (CD3e, ADAM15, PAK1, Sos1, and p85a) all three se-
lected RRT-SH3 domains showed substantially improved
binding when compared to native Hck-SH3. This improve-
ment was most striking in the case of CD3e and p85a, which
bound avidly to their cognate RRT-SH3 domains, but only
minimally or not at all to Hck-SH3. Similar to the case with
Nef, however, RT-loop manipulation could also provide a sig-
niﬁcant increase in aﬃnity towards ADAM15 and PAK1,
which could bind relatively well also to native Hck-SH3.
HRP-conjugated anti-M13 MAb
Myc-epitope
Anti-Myc MAb
SH3 domain
Ligand protein
A B
Fig. 2. Principle of the phage-assisted SH3-binding assay. SH3 ligand proteins of interest (A) or anti-Myc antibodies (B) were immobilised to plastic
wells that were subsequently incubated with diﬀerent dilutions of homogenous phage preparations expressing on their surface SH3 domains fused to
a Myc epitope peptide. In both cases (A and B) binding of the SH3-displaying phage particles to these wells was measured based on a chromogenic
reaction catalysed by a peroxidase-conjugated anti-phage antibody. The ratio of binding signals obtained in assay conﬁguration A vs. B was
considered as the measure of speciﬁc SH3-binding capacity of the displayed SH3 clone.
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Fig. 3. Relative increase in binding of RRT-SH3 domains to their cognate ligands compared to unmodiﬁed Hck-SH3. Three RRT-SH3 domains
selected for binding to PAK1 (P1  P3), ADAM15 (15.1–15.3), CD3e (e1–e3), Sos1 (S1–S3), or p85a (85.1–85.3) were compared with Hck-SH3 in
binding to their target proteins using the assay shown in Fig. 2. For comparison, multivalent phage particles carrying three RRT-SH3 domains (A1,
B4, and C1) previously selected for optimal binding to Nef from a monovalent phage library [11] were generated and tested in parallel for their
binding to Nef. In the case of each SH3 target protein the strongest binding signal observed was set to 100%, and binding of Hck-SH3 and the other
two RRT-SH3 domains was expressed relative to this. An average of at least three independent experiments is shown. Interassay variation is
indicated by the error bars.
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mine the absolute binding aﬃnities of these interactions. For
comparison, however, it is worth noting that when a more
quantitative assay based on puriﬁed recombinant proteins
was used to examine binding properties of the RRT-SH3 do-
mains A1, B4, and C1, they showed a 21- to 35-fold increased
capacity in binding to HIV-1 Nef compared to native Hck-
SH3 [11]. Considering that this was reﬂected only by a 3- to
5-fold increase in the binding signal of the current assay, the
relative increase in the capacity of these RRT-SH3 domains
to bind to CD3e, ADAM15, PAK1, Sos1, and p85a could very
well be more pronounced than apparent from the data shown
in Fig. 3.
Although our results revealed room for further biotechno-
logical optimisation, the natural RT-loop of Hck-SH3 plays
an important role in mediating the molecular contacts that ac-
count for the strong binding to Nef (KD 250 nM; [8]). There-
fore, one could predict that artiﬁcial targeting of Hck-SH3
for increased binding to CD3e, ADAM15, PAK1, Sos1, or
p85a via RT-manipulation would lead to a reciprocal loss in
aﬃnity for Nef. To test this hypothesis we used the phage-
based assay shown in Fig. 2 to examine the capacity these no-
vel RRT-SH3 domains to bind to Nef. As shown in Fig. 4, all
RRT-SH3 clones selected by non-Nef ligand proteins were in-
deed poorly competent for binding to Nef. Only two
ADAM15-selected clones (15.2 and 15.3) and one PAK1-se-
lected clone (P3) showed binding to Nef that was above 10%
of the signal observed for native Hck-SH3, and in many cases
no detectable Nef-binding could be observed. Thus, the amino
acid changes in these RRT-SH3 domains that provided them
with increased aﬃnity towards their targeted ligands led to
diminished aﬃnity towards Nef and presumably towards other
natural interactions of Hck-SH3 where the RT-loop is in-
volved.100
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Fig. 4. Loss of Nef-binding capacity relative to native Hck-SH3 of RRT-SH
p85a. The RRT-SH3 domains characterised in Fig. 3 for speciﬁc binding were
a natural high-aﬃnity SH3-binding partner of Hck. Measurements and dataVarious proteins scaﬀolds have been used to engineer and
display short peptides that can independently bind to ligands
of interest (see [18]), and recently the SH3-fold was also shown
to be useful for this purpose [19]. We have previously shown
that despite their highly increased aﬃnity for Nef, the RT-
loop-modiﬁed SH3 domains A1, B4, and C1 are still fully
dependent on canonical docking of the Hck-SH3 core region
to the consensus PxxP motif-containing binding site in Nef,
and cannot interact with a Nef mutant carrying a PxxP-to-
AxxA substitution [11]. Nevertheless, we wanted to make sure
that the novel RRT-SH3 domains generated in this study be-
haved as bona ﬁde SH3 domains, and the altered RT-loop se-
quences that provided them with novel binding properties did
not act independently of the rest of these SH3 domains. Since
many of the ligand proteins used in this study contained multi-
ple potential PxxP target sites, we used an alternative approach
to prevent docking of the RRT-SH3 domains to proline-rich
target peptides by introducing in these SH3 clones mutations
that disrupted one of the two proline binding pockets of
Hck-SH3. To this end we replaced both Asn131 and Tyr132 of
Hck with alanine residues, or alternatively mutated Tyr132
alone by introducing a more radical change, namely a nega-
tively changed residue (aspartic acid) that is not found in this
position in any human SH3 domain (see Fig. 1). Such mutants
were generated of two individual RRT-SH3 clones targeted for
binding to CD3e (e1 and e3), ADAM15 (15.1 and 15.2), PAK1
(P1 and P2), p85 (85.1 and 85.2) and Sos1 (S1 and S2), and
their capacity to bind to their cognate ligand was tested using
the same assays as above. None of the recombinant phages
expressing either NY-to-AA or NY-to-ND mutated RRT-
SH3 domains showed any binding to their cognate ligand pro-
teins (data not shown). Thus, we conclude that the radically al-
tered binding properties of the modiﬁed Hck-SH3 derivative
developed in this study can be attributed to a prominent, butNef
S1 S2 S3ε1 ε2 ε3 85.1 85.2 85.3
3 domains optimised for binding to PAK1, ADAM15, CD3e, Sos1, or
tested in parallel with unmodiﬁed Hck-SH3 for binding to HIV-1 Nef,
management was done as in Fig. 3.
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ligand selection.4. Discussion
In this study we have shown that manipulation of six resi-
dues in the non-conserved tip region of the RT-loop of Hck-
SH3 is suﬃcient to dramatically alter its ligand binding speci-
ﬁcity. The increased aﬃnity of Hck-SH3 towards the targeted
ligands was particularly striking in case of CD3e and p85a,
which showed no detectable binding to unmodiﬁed Hck-
SH3. This improved binding was in all cases accompanied by
a reciprocal loss in the ability of these engineered SH3 domains
to bind to HIV-1 Nef, a natural high-aﬃnity ligand of Hck-
SH3.
The experimental system used did not allow us to determine
the absolute binding aﬃnities of the engineered RRT-SH3 do-
mains towards their ligands. Based on a rough comparison
with the apparent strength of Nef-binding by native Hck-
SH3 and the Nef-targeted RRT-SH3 domains A1, B4, and
C1 it is likely that the aﬃnities of these interactions are in a
low nanomolar range or below, which indicates binding that
is tighter than seen in most natural SH3/ligand complexes.
However, knowing the precise aﬃnity values is not critical
for the present conclusions, which are fully supported by the
dramatic and reciprocal relative changes observed in the
strength of binding of Hck-SH3 to the targeted (CD3e,
ADAM15, PAK1, Sos1, or p85a) ligands vs. a natural high
aﬃnity partner (HIV-1 Nef) that could be achieved entirely
via RT-loop manipulation.
The failure of a given SH3 domain to interact with a protein
that binds avidly to another SH3 has generally been thought to
result from a poor ﬁt between the proline-rich region of the li-
gand and the peptide-binding groove of the former SH3.
Although the proximal regions of the RT-loop participate in
formation of the conserved SH3 peptide-binding surface, it
should be emphasised that the engineered residues unique to
each RRT-SH3 domain are located in the central tip region
of the RT-loop apart from the peptide-binding groove of
Hck-SH3 (see Fig. 1). Thus, our results extend this traditional
view of SH3 binding, and reveal a striking capacity of ‘‘addi-
tional’’ or ‘‘tertiary’’ interactions to inﬂuence SH3 ligand selec-
tion.
The implications of such a potentially dominating role of the
RT-loop (and perhaps other divergent loops in the SH3-fold)
over the consensus SH3 peptide docking surface are 2-fold.
First, the relevance of any conclusions regarding preferred
SH3-mediated protein interactions based on data on SH3
binding by isolated consensus peptide ligands might be limited.
In other words, because the strength and speciﬁcity of binding
may predominantly depend on molecular determinants outside
of the conserved SH3/peptide interface, diﬀerences in the aﬃn-
ity of this core interaction can in such cases not be used to
accurately predict the relative SH3-binding aﬃnities of the cor-
responding native ligand proteins.
Second, our results show that RT-loop manipulation may be
a generally feasible strategy for engineering of SH3 domains
with rationally altered ligand binding properties. We have pre-
viously shown that RRT-SH3 domains optimised for binding
to HIV-1 Nef can be used as potent intracellular inhibitorsof Nef function [12]. If necessary, the inhibitory potential of
RRT-SH3 domains might be further increased by fusing these
with other functional domains that could actively induce mis-
localisation or degradation of the complexed ligand. Delivery
of such inhibitory RRT-SH3 constructs using gene transfer
vectors could complement therapeutic strategies currently
being developed for inhibition of cellular signalling proteins
based on small molecular molecules or RNAi-mediated ap-
proaches.
Perhaps even more useful than the immediate inhibitory po-
tential of RRT-SH3 domains might be the possibility to use
their altered ligand speciﬁcities for reprogramming of cellular
signal transduction cascades. In elegant experiments by Lim
and colleagues protein engineering was used to create artiﬁcial
signalling proteins composed of a selected set of modular do-
mains derived from heterologous proteins [20]. These ratio-
nally designed proteins could carry out sophisticated
behaviours that are essential for signalling proteins operating
in complex cellular circuits, such as allosteric gating and mul-
ti-input signal integration, but in a non-physiological manner
that logically reﬂected their artiﬁcial compositions. SH3 do-
main belongs to a class of ubiquitous modular protein do-
mains found in nature, and therefore is a useful building
block for such synthetic switch proteins (a term coined by
the Lim laboratory) or related artiﬁcial signalling proteins.
The ability to manipulate the aﬃnity and selectivity of SH3 li-
gand recognition via RT-loop engineering provides a powerful
tool for enhancing such eﬀorts.
The RT-loop sequences of the RRT-SH3 domains targeted
for binding to CD3e, ADAM15, PAK1, Sos1, or p85a did
not closely resemble any naturally occurring SH3 domain.
Nevertheless, the molecular contacts used by the engineered
RRT-SH3 domains could be optimised but yet essentially sim-
ilar to those used by the corresponding RT-loop residues of
natural SH3 domains upon binding to the same ligands. Con-
versely, it is also possible that (at least in some cases) the RT-
loops of these RRT-SH3 domains interacted with their ligands
in a less natural manner, meaning that the target determinants
in the ligand would normally not be involved in SH3 binding.
Such speculations are of interest when thinking of the possible
role of the RT-loop as a general speciﬁcity and aﬃnity deter-
minant in SH3-mediated interactions in nature, but are less rel-
evant for the concept of exploiting ligand-targeted RRT-SH3
domains as inhibitors or modiﬁers of intracellular signalling
pathways.
The surprising ﬂexibility and potential dominance of the
RT-loop in determining SH3 ligand selection demonstrated
here using the SH3 domain of Hck as a test case suggest that
this approach could be used to target with high aﬃnity the
majority of cellular and microbial SH3 ligands. However, to
cover the full repertoire of SH3 target proteins, including those
containing highly atypical binding motifs, a panel of random-
ised libraries based on a set of divergent members of the SH3
domain family should perhaps be constructed. Moreover, with
the increasing knowledge about structure-function aspects of
ligand recognition by modular protein binding domains other
than SH3, the same approach might be extended to target
many more protein interactions, which could further improve
the tool box available for rational design of modulators of cel-
lular signalling to be used in experimental and possibly thera-
peutic applications.
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